Gyre Therapeutics
GYRE
Gyre Therapeutics (GYRE) news
Recent news
Gyre Therapeutics affirms FY2026 revenue guidance of $100.50 mln-$111 mln
Gyre Therapeutics (NASDAQ: GYRE) has reaffirmed its full-year 2026 revenue guidance of $100.50 million to $111.00 million, as outlined in its recent first-quarter 2026 earnings report . The company reported Q1 2026 revenue of $22.5 million, which marked a modest increase compared to the same period…
AInvest Wire · Aug 7, 2026Gyre Therapeutics appoints three new members to its board of directors
AInvest Wire · Jul 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.